IMCT-20ASSOCIATION OF SURVIVAL AND PROGRESSION-FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ NEWLY-DIAGNOSED GBM PATIENTS IN RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY WITH ICT-107 Article

Wen, Patrick, Reardon, David, Phuphanich, Surasak et al. (2015). IMCT-20ASSOCIATION OF SURVIVAL AND PROGRESSION-FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ NEWLY-DIAGNOSED GBM PATIENTS IN RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY WITH ICT-107 . NEURO-ONCOLOGY, 17(suppl_5), v112-v112. 10.1093/neuonc/nov218.20

cited authors

  • Wen, Patrick; Reardon, David; Phuphanich, Surasak; Aiken, Robert; Landolfi, Joseph; Curry, Wlliam; Zhu, Jay-Jiguang; Glantz, Michael; Peereboom, David; Markert, James; Larocca, Renato; O'Rourke, Donald; Fink, Karen; Kim, Lyndon; Gruber, Michael; Lesser, Glenn; Pan, Ed; Santos, Radleigh; Pinilla, Clemencia; Yu, John

authors

publication date

  • November 1, 2015

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3204 Immunology
  • 3211 Oncology and Carcinogenesis
  • Inflammatory and immune system

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • v112

end page

  • v112

volume

  • 17

issue

  • suppl_5